BIOACTIVE CONSTITUENTS AND ACUTE TOXICITY OF BLIGHIA SAPIDA CAPSULE EXTRACTS USING WISTAR RATS.

Blighia sapida, commonly known as Ackee, is a plant native to West Africa, with great cultural and therapeutic value, particularly in Western Nigeria. Traditionally, Blighia sapida capsule is used in western Nigeria to treat ecthyma in sheep and goats by heating it in hot ash. This process causes the capsule to release a liquid, which is then directly applied to the entire affected area of the skin. However, there is limited information available on its phyto-constituents and medicinal effects. This work examined the bioactive constituents, acute toxicity, and sub-acute toxicity of aqueous and ethanolic extracts of Blighia sapida capsule. Extraction of phytochemical constituents was carried out with distilled water and ethanol and was concentrated at 40ºC. The phytochemical constituents were determined using a variant 3800/4000 gas chromatography-mass spectrometry (GC-MS) machine. Lorke's method was employed to determine the acute toxicity of the aqueous and ethanolic extracts of Blighia sapida capsule. The GC-MS analysis revealed 15 bioactive compounds in both extracts, with kaempferol being the most abundant. Notable pharmacologically active compounds included pyrrolidin-2-ylmethanol, rutin, quinoline, apigenin, and naringenin. The study observed distinctive differences in aqueous and ethanolic extracts compound weights and peak areas. Acute toxicity study depicts that the lethal dose of aqueous and ethanolic extracts of Blighia sapida capsule is above 5000 mg/kg as no mortality was recorded in the oral administration of 10, 100, 1000, 1600, 2900, and 5000 mg/kg of aqueous and ethanolic extracts. Sub-acute toxicity results indicated no significant adverse effects on kidney and liver function, although some variations in biochemical parameters were observed. Histological analysis showed normal renal and hepatic architecture in treated animals. This study demonstrated that aqueous and ethanolic extracts of Blighia sapida capsule exhibited no acute toxicity and minimal sub-acute toxicity, suggesting they are safe for consumption at the tested doses.

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflict of interest.